All Industries

Top healthtech Companies

659 healthtech companies, sorted by total funding raised.

LENZ TherapeuticsIPO

Late-stage ophthalmic pharmaceutical company commercializing VIZZ eye drops for presbyopia and bl...

Burlingame, United States51–200healthtech, biotech
Private Equity·$160.5M·Jul 2024
Relmada TherapeuticsIPO

Clinical-stage biotech developing innovative therapies for oncology and CNS disorders including d...

New York, United States11–50healthtech, biotech
Private Equity·$160.0M·Jan 2026
Tyra BiosciencesIPO

Clinical-stage biotech developing next-generation precision medicines targeting kinase biology fo...

Carlsbad, United States11–50healthtech, biotech
Series B·$156.0M·Mar 2021
Syndax PharmaceuticalsIPO

Commercial-stage oncology biopharmaceutical developing first-in-class therapies for acute leukemi...

Waltham, United States51–200healthtech, biotech
Series C·$152.6M·Aug 2015
Vor Biopharma Inc.IPO

Clinical-stage biotechnology company developing cell and genome engineering therapies for autoimm...

Cambridge, United States51–200healthtech, Biotech
Series B·$152.0M·Jul 2020
Legend Biotech CorporationIPO

Legend Biotech is a global clinical-stage biotechnology company developing cell therapies, includ...

Somerset, United States1001–5000healthtech, Biotech
Series A·$150.5M·Apr 2020
Shoulder InnovationsIPO

Medical device company developing InSet glenoid technology to improve shoulder arthroplasty outco...

Holland, United States11–50Healthcare, healthtech
Convertible·$149.2M·Jul 2025
Ideaya BiosciencesIPO

Clinical-stage precision medicine oncology company developing targeted therapeutics using molecul...

South San Francisco, United States201–500Biotech, Drug Discovery
Series A·$140.0M·Jul 2024
ArdelyxIPO

Focused on the discovery and development of novel therapeutics acting exclusively in the gastroin...

Fremont, United States201–500Biopharmaceutical, Therapeutics
Private Equity·$140.0M·Jul 2016
SurrozenIPO

Surrozen is a clinical-stage biotech developing Wnt pathway-based regenerative medicines, with a ...

South San Francisco, United States11–50Biotech, Therapeutics
Series C·$133.0M·Jun 2020
SAB Biotherapeutics, Inc.

R&D company with 3 SBIR/STTR awards from Department of Health and Human Services.

Sioux Falls, United States11–50healthtech, Biotech
Growth Equity·$131.1M·Oct 2023
Monte Rosa TherapeuticsIPO

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-...

Boston, United States51–200Biotech, Drug Discovery
Series C·$127.5M·Mar 2021
Tenax TherapeuticsIPO

Tenax Therapeutics is a Phase 3 pharmaceutical company developing novel cardiopulmonary therapies...

United Stateshealthtech, Biotech
Corporate Round·$125.0M·Mar 2025
Taysha Gene TherapiesIPO

Clinical-stage gene therapy company focused on discovering, developing, and commercializing treat...

Dallas, United States51–200healthtech, Biotech
Series B·$125.0M·Aug 2020
Burning Rock Biotech LimitedIPO

Global diagnostics company applying next-generation sequencing technology in precision oncology f...

Guangzhou, China201–500healthtech, Biotech
Series C·$120.0M·Dec 2019
Adaptive BiotechnologiesIPO

Immune-driven medicine company mapping the human adaptive immune system

Seattle, United States501–1000Biotech, Healthcare
Series D·$120.0M·May 2019
MBX BiosciencesIPO

Advancing potential breakthrough medicines for rare endocrine diseases of substantial medical nee...

Carmel11–50healthtech
Series C·$113.1M·Aug 2024
Lineage Cell TherapeuticsIPO

Clinical-stage biotechnology company developing novel cellular therapies to treat serious unmet m...

Carlsbad, United States51–200healthtech, Biotech
Corporate Round·$110.5M·Jan 2022
Prelude Therapeutics IncorporatedIPO

Precision oncology company developing innovative medicines for cancer patients with high unmet me...

Wilmington, United Stateshealthtech, biotech
Series C·$110.0M·Aug 2020
Kyverna TherapeuticsIPO

Kyverna is a cell therapy company engineering and developing a new class of curative living medic...

Emeryville, United States51–200Life Sciences, healthtech
Series B·$110.0M·Aug 2023
Globus MedicalIPO

Publicly traded orthopedic medical device company that develops, manufactures, and distributes mu...

Audubon, United States1001–5000healthtech
Series E·$110.0M·Aug 2007
Inhibikase TherapeuticsIPO

Clinical-stage pharmaceutical company developing small molecule kinase inhibitor therapeutics for...

Atlanta, United States11–50healthtech, Biotech
Private Equity·$110.0M·Oct 2024
Palvella TherapeuticsIPO

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on dev...

Wayne, United States11–50healthtech, Biotech
Series D·$109.7M·Jan 2023
Tenaya TherapeuticsIPO

Clinical-stage biotech developing potentially curative gene therapies targeting the underlying dr...

South San Francisco, United States51–200Biotech, Healthcare
Series C·$106.0M·Mar 2021
Voyager TherapeuticsIPO

Biotechnology company leveraging human genetics to develop treatments and cures for neurological ...

Lexington, United States51–200healthtech, Biotech
Series B·$105.0M·Apr 2015